Eurofins Genomics Europe, a leader in genomic products and services, is further expanding its SARSCoV-2 full genome sequencing capacity.
The laboratory in Constance, Germany, has sequenced more than 100,000 SARS-CoV-2 samples from 23 countries in the past three months. Eurofins Genomics Europe’s “ARTIC SARS-CoV-2 Whole Genome Sequencing” service includes next-generation sequencing (NGS) and detailed reporting for universal end-to-end surveillance of pandemic development, tracking the emergence and dynamics of existing and new mutational Variants of Concern.
The service was launched in December 2020 and was designed to facilitate global genomic scientific insights into SARS-CoV-2, providing scientists with the right tools to identify fast and viable measures against the pandemic. With an increasing focus on Variants of Concern, the service was used by many countries and European organisations to support national responses to observed mutant variants. With a turnaround time of as little as 5 days and a capacity of 35,000 viral genomes per week, Eurofins Genomics Europe continues to contribute to the fight against the pandemic. Future investments will lead to a further increase in capacity in the coming weeks.
The “SARS-CoV-2 Full-length Genome Sequencing” service provides Eurofins Genomics’ customers with a fully assembled sequence of the viral ssRNA genome. It enables accurate lineage and variant identification, surveillance of emerging and spreading Variants of Concern, as well as phylogenetic analyses between locally and regionally different viral isolates. A sophisticated bioinformatics analyses and reporting pipeline provides comprehensive SNP and variant reporting, including lineage classification, facilitating conclusive interpretation of data.
Eurofins Genomics Europe’s “SARS-CoV-2 Full-length Genome Sequencing” service is an important part of the Eurofins Group’s commitment to contributing to the global response to the SARS-CoV-2 crisis. Eurofins Genomics Europe supports scientists from across the world in their vital work by providing them with the right tools to facilitate genomic research on SARS-CoV-2. The COVID-19 product range covers the entire spectrum of genomic possibilities: SARS-CoV-2 qPCR tests, assays, plasmid controls, RT-PCR kits, wastewater and surface tests.
Further information on Eurofins Genomics Germany’s entire COVID-19 testing portfolio can be found on https://www.eurofinsgenomics.eu/en/covid-19/
More information on the “SARS-CoV-2 Full-length Genome Sequencing” service can be found on https://eurofinsgenomics.eu/en/next-generation-sequencing/applications/artic-sars-cov-2-rna-seq/